Denali Therapeutics Inc (OQ:DNLI)

Nov 06, 2019 04:30 pm ET
Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2019, and provided...
Sep 04, 2019 09:00 am ET
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of LRRK2 inhibitor DNL151 in...
Aug 06, 2019 04:30 pm ET
Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2019, and provided...
Aug 05, 2019 09:00 am ET
Denali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that its partner Sanofi has commenced dosing of DNL758, a peripherally...
Jun 11, 2019 09:00 am ET
Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that the FDA granted Orphan Drug Designation (“ODD”) and Rare Pediatric Disease...
May 08, 2019 04:30 pm ET
Denali Therapeutics Reports First Quarter 2019 Financial Results
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2019. First Quarter 2019...
Mar 12, 2019 09:00 am ET
Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018...
Feb 19, 2019 07:55 am ET
New Research: Key Drivers of Growth for Walgreens Boots Alliance, Live Nation Entertainment, Denali Therapeutics, Haynes International, NV5 Global, and Johnson Outdoors — Factors of Influence, Major I
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Walgreens Boots Alliance, Inc. (NASDAQ:WBA), Live Nation Entertainment,...
Feb 15, 2019 09:00 am ET
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of DNL747 in patients with...
Jan 08, 2019 09:00 am ET
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of DNL747 in patients with...
Dec 10, 2018 09:00 am ET
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of DNL201 in patients with...
Nov 19, 2018 04:30 pm ET
Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced positive results from its Phase 1 healthy volunteer study of DNL747, a brain...
Nov 08, 2018 04:30 pm ET
Denali Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights and Announces the Appointment of Jennifer Cook to Board of Directors
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2018, provided...
Nov 01, 2018 02:00 am ET
Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors for the Treatment of Neurological and Inflammatory Diseases
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it will collaborate with Sanofi on the development of multiple RIPK1...
Oct 23, 2018 08:40 am ET
Report: Exploring Fundamental Drivers Behind Q2, Badger Meter, Tiffany, Walgreens Boots Alliance, Intrexon, and Denali Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Q2 Holdings, Inc. (NYSE:QTWO), Badger Meter, Inc. (NYSE:BMI), Tiffany ...
Oct 03, 2018 09:00 am ET
CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials
CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the glo
Oct 03, 2018 09:00 am ET
CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials
CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation carrier Parkinson’s disease (“PD”) patients. CENTOGENE will conduct a targeted global...
Aug 09, 2018 04:30 pm ET
Denali Therapeutics Reports Second Quarter 2018 Financial Results
Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2018. Second Quarter 2018...
Aug 07, 2018 04:30 pm ET
Denali Therapeutics Appoints Dana Andersen, Ph.D., as Chief Technical and Manufacturing Officer
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that Dr. Dana Andersen has joined the company as Chief Technical and...
Aug 01, 2018 04:30 pm ET
Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program for Parkinson’s Disease
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced positive results from its Phase 1 clinical study with DNL201, a small molecule...
May 30, 2018 04:05 pm ET
Denali Therapeutics Announces Early Exercise of Its Option to Acquire F-star Gamma
Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it has exercised its option to acquire all outstanding shares in F-star...
May 11, 2018 08:00 am ET
Denali Therapeutics Reports First Quarter 2018 Financial Results
Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2018. First Quarter...
Mar 19, 2018 08:00 am ET
Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financia
SOUTH SAN FRANCISCO, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it has commenced dosing of its small molecule...
Feb 08, 2018 09:00 am ET
Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines
BASEL, Switzerland and SOUTH SAN FRANCISCO, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Lonza Pharma & Biotech and Denali Therapeutics (NASDAQ:DNLI) announced today an exclusive strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases. The agreement covers...
Jan 05, 2018 07:00 am ET
Takeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative Diseases
Takeda Pharmaceutical Company Limited (TSE: 4502) and Denali Therapeutics (NASDAQ: DNLI) today announced that they have entered into a strategic option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases. Each program is directed to
Dec 20, 2017 05:50 pm ET
Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson’s Disease
DNL201 Achieves Target Engagement, FDA Lifts Partial Clinical Hold on DNL201, and DNL151 Moves into Clinical Testing
Dec 12, 2017 04:10 pm ET
Denali Therapeutics Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the closing of its initial public offering of 15,972,221 shares of its common stock at a price to the public of $18.00...
Dec 08, 2017 02:21 pm ET
Nasdaq Welcomes Denali Therapeutics, Inc. (NASDAQ: DNLI) to The Nasdaq Stock Market
NEW YORK, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq:DNLI), a biopharmaceutical company focused on the discovery and development of therapies for patients with neurodegenerative disease, visited the Nasdaq MarketSite in Times Square today in celebration...
Dec 07, 2017 07:08 pm ET
Denali Therapeutics Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the pricing of its initial public offering of 13,888,888 shares of its common stock at a price to the public of $18.00...